DUBLIN (dpa-AFX) - Accenture plc (ACN) Thursday announced strategic
investment in Turbine, a company building cell simulation platform for
interpreting human biology.

Turbine's proprietary Simulated Cell platform uses machine learning to
understand how human cells make decisions.

Accenture has invested in Turbine through Accenture Ventures, that invests in
growth stage Deep-tech B2B start-ups.

Turbine's platform is being validated with leading pharma companies to identify
promising drug targets, select patients who are most likely to benefit from
therapy, and identify combination therapy regimens that can be benefitted for
certain patients. This allows Turbine to suggest new treatments as well as point
out drugs that are likely to fail in clinical trials.

Petra Jantzer, a senior managing director and global lead of the Accenture Life
Sciences business, said, 'Turbine's Simulated Cell platform has emerged as a
valuable tool for global biopharma companies to gain insights into the
intricacies of biological systems, which can lead to the development of targeted
treatments. Our investment reflects our commitment to supporting technology and
digital capabilities that drive innovation in AI-based drug discovery, all with
the goal of providing more effective treatments and enhancing patient care.'



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX